Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field
Endpoints
Tue, 06/27/17 - 09:38 am
Tags:
Alder Biopharma, migraines, clinical trials, eptinezumab, Eli Lilly, Amgen, Novartis, Merck
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Tags:
Europe, EMA, hepatitis C, multiple sclerosis, breast cancer, renal cell carcinoma, AbbVie, Maviret, Gilead Sciences, Vosevi, Biogen, Amgen, Samsung Bioepis, biosimilars, Humira, Novartis, Kisqali, EUSA, Fotivda
Amgen Defends Drug Pipeline, Says the Best is Yet to Come
TheStreet.com
Fri, 06/23/17 - 09:41 am
Tags:
Amgen, R&D
5 Most Profitable Big Pharma Stocks on the Market Right Now
Motley Fool
Wed, 06/21/17 - 09:37 am
Tags:
Big Pharma, Gilead Sciences, Amgen, Novartis, Biogen, Bristol-Myers Squibb
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Mon, 06/12/17 - 09:24 pm
Tags:
Amgen, Novartis, Supreme Court, biosimilars, Neulasta, FDA, Coherus Biosciences
Amgen Sues FDA After Agency Denies Pediatric Exclusivity for SENSIPAR
FDA Law Blog
Wed, 05/31/17 - 09:28 am
Tags:
Amgen, FDA, pediatric exclusivity, Sensipar, patents, chronic kidney disease
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
Fierce Pharma
Mon, 05/29/17 - 12:00 pm
Tags:
FDA, advisory panels, Pfizer, biosimilars, Amgen, Epogen, Procrit, anemia, JNJ
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
Fierce Pharma
Wed, 05/24/17 - 10:51 am
Tags:
Pfizer, Epogen, biosimilars, FDA, advisory panels, Amgen, anemia
Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug
Fierce Pharma
Mon, 05/22/17 - 09:45 am
Tags:
Amgen, romosozumab, Radius Health, UCB Pharma, Tymlos, osteoporosis
7 Areas to watch from the ASCO abstracts
BioPharma Dive
Fri, 05/19/17 - 11:35 am
Tags:
ASCO 2017, oncology, Incyte, Merck, Eli Lilly, CAR-T, NewLink Genetics, Amgen, Roche, Kite Pharma, Juno Therapeutics
Amgen inks first money-back guarantee for Repatha
BioPharma Dive
Wed, 05/3/17 - 10:06 am
Tags:
Amgen, Repatha, insurers
With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry
Endpoints
Mon, 05/1/17 - 10:57 am
Tags:
Amgen, Radius Health, osteoporosis, Tymlos, romosozumab
These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016
Motley Fool
Sat, 04/29/17 - 10:12 am
Tags:
earnings, drug pricing, Biogen, Eli Lilly, AbbVie, Allergan, Merck, Pfizer, Amgen
Three Biotechs Enter…One Biotech Gains
Barron's
Thu, 04/27/17 - 05:55 pm
Tags:
earnings, Celgene, Alexion, Amgen
Amgen first-quarter profit exceeds Street estimates on lower costs
Yahoo/Reuters
Wed, 04/26/17 - 09:45 pm
Tags:
Amgen, earnings
U.S. top court grapples over making copycat biologics available sooner
Yahoo/Reuters
Wed, 04/26/17 - 09:39 pm
Tags:
biosimilars, Neupogen, Amgen, Supreme Court
Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Endpoints
Wed, 04/26/17 - 11:29 am
Tags:
migraines, Amgen, Covance, erenumab
Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?
Motley Fool
Tue, 04/25/17 - 11:10 am
Tags:
Valeant Pharmaceuticals, Siliq, drug pricing, brodalumab, psoriasis, AstraZeneca, Amgen
Earnings Preview: What To Expect From Amgen On Wednesday
Forbes
Tue, 04/25/17 - 11:08 am
Tags:
earnings, Amgen
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Endpoints
Tue, 04/25/17 - 11:03 am
Tags:
Novartis, Amgen, CGRP blockers, migraines, erenumab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.